Skip to main content
. 2021 Feb 27;48(7):2200–2211. doi: 10.1007/s00259-021-05246-x

Table 3.

Detailed information on the diagnostic impact of the second PET scan in the two diagnostic pathways (AMY-TAU and TAU-AMY)

Diagnostic
pathway
N of
patients
T0
diagnosis
First
PET scan
T1
diagnosis
Second
PET scan
T2
diagnosis
Observations
AMY-TAU 8 AD AMY+ AD TAU– Non-AD

• Discordant PET results

• Same diagnosis at T0 and T1

1 Non-AD AMY+ AD TAU– Non-AD

• Discordant PET results

• T1 diagnosis changed after first PET scan

1 AD AMY– Non-AD TAU+ AD

• Discordant PET results

• T1 diagnosis changed after first PET scan

1 Non-AD AMY– Non-AD TAU+ AD

• Discordant PET results

• Same diagnosis at T0 and T1

1* AD AMY– Non-AD TAU– AD

• Concordant PET results

• T1 diagnosis changed after first PET scan

TAU-AMY 1 AD TAU– AD AMY– Non-AD

• Concordant PET results

• Same diagnosis at T0 and T1

4 Non-AD TAU– Non-AD AMY+ AD

• Discordant PET results

• Same diagnosis at T0 and T1

2 AD TAU– Non-AD AMY+ AD

• Discordant PET results

• T1 diagnosis changed after first PET scan

1 Non-AD TAU+ Non-AD AMY+ AD

• Concordant PET results

• Same diagnosis at T0 and T1

AMY+/−: amyloid positive/negative, TAU+/−: tau positive/negative

This table includes only patients who changed diagnosis after amyloid-PET (n = 8) or tau-PET (n = 12) presented as the second exam

*The only case in which the diagnosis changed after a consistent PET result was a patient with a T1 diagnosis of MCI not due to AD based on a negative amyloid-PET whose diagnosis changed to AD at T2 after a negative tau-PET scan (Braak stage = I–III)